IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+12.69%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$269M
AUM Growth
-$14.1M
(-5%)
Cap. Flow
+$21.1M
Cap. Flow
% of AUM
7.85%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
130
New
23
Increased
25
Reduced
23
Closed
23
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$15.8M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$13.4M |
| 3 |
Immunovant
IMVT
|
$11.4M |
| 4 |
Akero Therapeutics
AKRO
|
$10.1M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$9.45M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$12.2M |
| 2 |
Merck
MRK
|
$11.5M |
| 3 |
Biohaven
BHVN
|
$8.36M |
| 4 |
Insmed
INSM
|
$8.34M |
| 5 |
IDEAYA Biosciences
IDYA
|
$7.39M |
Sector Composition
| 1 | Healthcare | 97.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
AstraZeneca
AZN
$254B
| – | – |
0
| – | – |
|
|
BCYC
127
Bicycle Therapeutics
BCYC
$483M
| – | – |
-203,037
| Closed | -$5.18M |
|
|
BLUE
128
DELISTED
bluebird bio
BLUE
| – | – |
-20,631
| Closed | -$1.36M |
|
129
Biomea Fusion
BMEA
$109M
| – | – |
-275,875
| Closed | -$6.06M |
|
130
BioMarin Pharmaceuticals
BMRN
$10.9B
| – | – |
0
| – | – |
|